In consideration of the market penetration.I'm in the same boat,...

In consideration of the market penetration.

I'm in the same boat, having held since listing, or near enough to. I work in Pathology labs and thought it was a no brainer, still do, only wasn't anticipating the brainlessness of the status quo.

Agree it's just not progressing the Earnings bit of the P/E to justify hanging in there, doubling revenues each period or year at one stage........ I just don't think it's a very sexy disease.

The low false positivity driving economic viability might appear to a drug company as someone eating their lunch. Powerful incumbents profiting from the status quo will at the very least indifferent to such arguments. As will the ticket clippers, sorry doctors, who's follow up consults equate to repeat customers.

No brainer indeed, oh how the nieve (thats me) come to learn.